

Biogen (USA): Demerger of Bioverativ (USA) Changes in FTSE Indices

26 January 2017

Subject to the completion of the demerger of Bioverativ (USA, non-constituent) from Biogen (USA, constituent), please see details of affected indexes and effective dates below:

Index	Effective From Start of Trading
FTSE All-World Index	02 February 2017
FTSE MPF All-World Index	02 February 2017
FTSE Developed Index	02 February 2017
FTSE Global Large Cap Index	02 February 2017
FTSE Multinationals Index	02 February 2017
FTSE Global Style Index	02 February 2017
FTSE Global 100 Index**	02 February 2017

Effective from start of trading on 02 February 2017, Bioverativ's ICB Classification will be 4573 (Biotechnology).

The Value and Growth rating for Bioverativ within the FTSE Global Style Index are as follows: Value: 0, Growth: 100.

*The number of shares is based on the demerger terms of 0.5 shares of Bioverativ for every Biogen share held.

The FTSE Global 100 Index will have 101 constituents effective from the open of 02 February 2017. The closing price of Bioverativ on 02 February 2017 will be used to rank removal of the extra company in the index. The removal will be effective for **06 February 2017.

For further information please contact FTSE Russell Client Services at info@ftserussell.com or call:

Australia	+1800 653 680
Hong Kong	+852 2164 3333
Japan	+81 3 3581 2764
London	+44 (0) 20 7866 1810
New York	+1866 551 0617

Alternatively please visit our website at www.ftserussell.com

[Terms of Use](#) | Copyright © 2017 FTSE Russell